Related Experiment Video
Updated: Jul 16, 2026
10:35
Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
Published on: December 26, 2017
Dual acting anti-inflammatory drugs
S Leone1, A Ottani, A Bertolini
1Division of Clinical Pharmacology, School of Medicine, University of Modena and Reggio Emilia, Modena, Italy.
Current Topics in Medicinal Chemistry
|February 20, 2007
Summary
Dual acting anti-inflammatory drugs inhibit both COX and 5-LOX, offering advantages over NSAIDs. These novel compounds show promise for inflammatory, cancer, and neurodegenerative diseases.
Area of Science:
- Pharmacology
- Medicinal Chemistry
Background:
- Classical nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit cyclooxygenases (COX) but can cause gastrointestinal issues by increasing leukotriene (LT) production.
- Leukotrienes are pro-inflammatory mediators involved in inflammation, bronchoconstriction, and increased vascular permeability, with LTB(4) being a potent chemotactic agent.
Purpose of the Study:
- To explore the design and potential of dual-acting drugs that inhibit both COX and 5-lipoxygenase (5-LOX).
- To evaluate the therapeutic advantages of dual COX/5-LOX inhibition over traditional NSAIDs and selective COX-2 inhibitors for various diseases.
Main Methods:
- Design and synthesis of novel chemical entities targeting both COX and 5-LOX enzymes.
- Preclinical evaluation of dual inhibitors in models of inflammation, cancer, and neurodegeneration.
Main Results:
- Dual inhibitors retain anti-inflammatory activity while mitigating drawbacks associated with NSAIDs, such as reduced gastroprotection.
- These compounds demonstrate potential in managing inflammatory conditions, exhibiting anticancer effects by preventing shunting to leukotriene pathways, and offering neuroprotection.
Conclusions:
- Dual COX and 5-LOX inhibitors represent a promising therapeutic strategy for inflammatory diseases, potentially offering better outcomes in cancer and neurodegenerative conditions.
- The ability to inhibit leukotriene synthesis without impairing beneficial lipoxin production highlights the therapeutic potential of these novel agents.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...